Jena, Germany | 19 April 2021 | Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 767.4 million in the first half of fiscal year 2020/21 (previous year: EUR 714.9 million). This corresponds to a revenue development of +7.3% vs. the past year (after adjustment for currency effects : +10.5%). In the second quarter of FY 2020/21, revenue amounted to EUR 398.5 million (past year: EUR 345.3 million) – a growth rate of +15.4% (after adjustment for currency effects: +18.8%).
Earnings before interest and taxes (EBIT) amounted to EUR 162.7 million in the first half of FY 2020/21 (past year: EUR 102.5 million). EBIT margin (EBIT / revenue) was 21.2% (past year 14.3%). In the second quarter of FY 2020/21, EBIT amounted to EUR 89.3 million (past year: EUR 45.7 million). EBIT margin was 22.4% (past year: 13.2%). EBIT benefitted in part from a favorable development of product mix as well as a continuing low level of sales and marketing expenses due to the COVID-19 pandemic, compared to the past year.
Earnings per share (EPS) amounted to EUR 1.12 (past year: EUR 0.71) for the first half of FY 2020/21. In the second quarter, EPS amounted to EUR 0.60 (past year: EUR 0.28).
Full results for the first half 2020/21 will be published on May 10, 2021.
During the further course of FY 2020/21, the company expects an ongoing normalization of business development. This expectation is based on the assumption that there will be no renewed deterioration in the global pandemic situation.
Revenue is expected to reach around EUR 1.6 billion (past year: EUR 1,335.5 million) in FY 2020/21. EBIT margin for FY 2020/21 is projected to reach a level of approximately 20% (past year: 13.3%), with significant support from lower than usual sales and marketing expenses in the current year. The company’s mid-term margin outlook remains unchanged: to generate an EBIT margin sustainably above the level of 18%.
1 Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
2 Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).
3 Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,290 employees worldwide, the Group generated revenue of €1,335.5m in fiscal year 2019/20 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med